We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy?
Read MoreHide Full Article
Key Takeaways
VEEV will fully transition from CRM to its Vault platform by Sept 2025, gaining full tech stack control.
VEEV's life sciences focus drives Vault CRM adoption, with over 80 deployments and AI tools launching in 2025.
CRM is expanding in life sciences via Life Sciences Cloud and Agentforce AI, reaching $100M ARR in 90 days.
A significant shift is underway in the enterprise software landscape, particularly within the life sciences customer relationship management (CRM - Free Report) market. Veeva Systems (VEEV - Free Report) , a long-time partner of Salesforce (CRM - Free Report) , has announced it will end its reliance on Salesforce’s cloud infrastructure by September 2025. This strategic decision marks the beginning of Veeva’s transition to its proprietary Vault platform, signaling a decisive move toward platform independence and deeper industry specialization.
The split sets up a compelling faceoff between two companies now heading down very different paths. Veeva is sharpening its focus on life sciences by building vertically integrated solutions tailored to the sector’s needs. At the same time, Salesforce is making a deliberate push into life sciences with its own purpose-built CRM offering. Both companies are accelerating investments in AI and product innovation, but their visions for capturing long-term growth are rapidly diverging. For investors, the key question is which company offers the stronger roadmap in this evolving market.
Price Performance & Valuation of VEEV & CRM
Shares of Veeva have gained 35.7%, while CRM stock has plunged 21.1% in the year-to-date period.
Image Source: Zacks Investment Research
From a valuation standpoint, CRM looks slightly more attractive than VEEV. According to the price-to-book ratio, Salesforce’s shares currently trade at 4.15X, which is lower than Veeva's 7.50X.
Image Source: Zacks Investment Research
Platform Control & Industry Focus: Who Owns the Vertical?
Veeva has long differentiated itself by serving a single industry—life sciences—with laser focus. That specialization is now reaching a new level as the company prepares to fully shift its CRM operations from Salesforce’s infrastructure to its own Vault platform by September 2025. This move is more than just a tech transition. It gives Veeva full control over its software stack, allowing it to tailor features, optimize performance, and potentially expand margins without depending on a third-party host. More importantly, it strengthens Veeva’s position as a vertically integrated player with deep regulatory and workflow understanding, something horizontal platforms often struggle to replicate in niche markets.
Salesforce, meanwhile, brings the power of a highly adaptable and proven CRM infrastructure that serves thousands of enterprise customers across industries. Its recent push into life sciences through the introduction of a dedicated Life Sciences Cloud reflects a strategic intent to expand within this high-value vertical. While its approach is broader by design, Salesforce benefits from scale, flexibility, and a robust ecosystem that supports rapid customization through its platform tools. With the partnership ending, Salesforce now has the freedom to compete directly in life sciences CRM, and its entry could accelerate innovation and choice in the market without being constrained by a single client relationship.
AI & Product Innovation: Whose Tech Vision Leads?
Veeva is taking a focused approach to AI by building capabilities directly into its Vault platform. In April 2025, it launched Veeva AI, which integrates LLM agents and shortcuts across clinical, regulatory, and commercial apps. Features like Vault CRM Bot, Voice Control, and MLR Bot are set to roll out by late 2025, automating tasks such as pre-call planning and content compliance. Veeva also released the Direct Data API to enable faster, secure access to Vault data, supporting integrations with platforms like Snowflake and Databricks. These innovations are already gaining traction, with over 80 Vault CRM deployments and a goal of exceeding 200 by fiscal 2026.
Salesforce is advancing AI at scale through Agentforce, a platform of prebuilt AI assistants embedded across its suite. Within 90 days of launch, Agentforce reached 3,000 paying customers and crossed $100 million in ARR. It connects with Tableau, MuleSoft, and Data Cloud to unify workflows and supports the Life Sciences Cloud Partner Network, which includes integrations with H1, ComplianceQuest, Box, and others. The company has also brought on AI-focused board members and continues to emphasize responsible adoption, aiming to augment human roles rather than replace them.
The Road Ahead: Who’s Better Positioned for CRM Leadership in Life Sciences?
Veeva is focused on finalizing its shift to the Vault platform, aiming to boost margins and accelerate innovation with full control over its tech stack. Its AI roadmap, including tools like Vault CRM Bot and Voice Control, is designed to enhance productivity and compliance for life sciences users. With strong early adoption of Vault CRM and expanding enterprise relationships, Veeva is positioning itself as the go-to vertical platform for the sector.
Salesforce is pursuing growth through its broad platform and expanding presence in life sciences via its dedicated cloud and AI-led offerings. Backed by a strong ecosystem and new integrations with healthcare partners, Salesforce is embedding Agentforce AI across its products. Its scale, flexibility, and ability to serve complex enterprise needs provide a strong foundation as it targets more specialized verticals like life sciences.
How Do Zacks Estimates Compare for VEEV & CRM?
The Zacks Consensus Estimate for VEEV’s fiscal 2026 sales implies a year-over-year growth of 12.78%. For fiscal 2026, the earnings per share are projected to be $7.64, up 15.76% year over year. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for CRM’s fiscal 2026 sales and earnings implies year-over-year growth of 8.64% and 10.78%, respectively. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
VEEV or CRM: Which Is the Smarter Buy?
Veeva and Salesforce represent two powerful but contrasting approaches to the life sciences CRM market—one focused on deep vertical integration, the other leveraging broad enterprise reach. Veeva currently holds a Zacks Rank #2 (Buy), reflecting positive sentiment and growing confidence in its post-Salesforce roadmap. Its Growth Score of ‘A’ highlights strong potential in revenue acceleration, margin expansion, and product adoption. Salesforce, meanwhile, carries a Zacks Rank #3 (Hold) but also maintains a Growth Score of ‘A’, supported by its scale, product breadth, and AI-led innovation strategy. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Both companies are positioned for long-term relevance, but Veeva’s focused strategy, platform control, and growing traction in life sciences give it the edge for investors seeking targeted exposure in this vertical. Salesforce remains a strong contender with scale and innovation, yet Veeva’s clarity and execution make it the more compelling pick in this CRM faceoff.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy?
Key Takeaways
A significant shift is underway in the enterprise software landscape, particularly within the life sciences customer relationship management (CRM - Free Report) market. Veeva Systems (VEEV - Free Report) , a long-time partner of Salesforce (CRM - Free Report) , has announced it will end its reliance on Salesforce’s cloud infrastructure by September 2025. This strategic decision marks the beginning of Veeva’s transition to its proprietary Vault platform, signaling a decisive move toward platform independence and deeper industry specialization.
The split sets up a compelling faceoff between two companies now heading down very different paths. Veeva is sharpening its focus on life sciences by building vertically integrated solutions tailored to the sector’s needs. At the same time, Salesforce is making a deliberate push into life sciences with its own purpose-built CRM offering. Both companies are accelerating investments in AI and product innovation, but their visions for capturing long-term growth are rapidly diverging. For investors, the key question is which company offers the stronger roadmap in this evolving market.
Price Performance & Valuation of VEEV & CRM
Shares of Veeva have gained 35.7%, while CRM stock has plunged 21.1% in the year-to-date period.
Image Source: Zacks Investment Research
From a valuation standpoint, CRM looks slightly more attractive than VEEV. According to the price-to-book ratio, Salesforce’s shares currently trade at 4.15X, which is lower than Veeva's 7.50X.
Image Source: Zacks Investment Research
Platform Control & Industry Focus: Who Owns the Vertical?
Veeva has long differentiated itself by serving a single industry—life sciences—with laser focus. That specialization is now reaching a new level as the company prepares to fully shift its CRM operations from Salesforce’s infrastructure to its own Vault platform by September 2025. This move is more than just a tech transition. It gives Veeva full control over its software stack, allowing it to tailor features, optimize performance, and potentially expand margins without depending on a third-party host. More importantly, it strengthens Veeva’s position as a vertically integrated player with deep regulatory and workflow understanding, something horizontal platforms often struggle to replicate in niche markets.
Salesforce, meanwhile, brings the power of a highly adaptable and proven CRM infrastructure that serves thousands of enterprise customers across industries. Its recent push into life sciences through the introduction of a dedicated Life Sciences Cloud reflects a strategic intent to expand within this high-value vertical. While its approach is broader by design, Salesforce benefits from scale, flexibility, and a robust ecosystem that supports rapid customization through its platform tools. With the partnership ending, Salesforce now has the freedom to compete directly in life sciences CRM, and its entry could accelerate innovation and choice in the market without being constrained by a single client relationship.
AI & Product Innovation: Whose Tech Vision Leads?
Veeva is taking a focused approach to AI by building capabilities directly into its Vault platform. In April 2025, it launched Veeva AI, which integrates LLM agents and shortcuts across clinical, regulatory, and commercial apps. Features like Vault CRM Bot, Voice Control, and MLR Bot are set to roll out by late 2025, automating tasks such as pre-call planning and content compliance. Veeva also released the Direct Data API to enable faster, secure access to Vault data, supporting integrations with platforms like Snowflake and Databricks. These innovations are already gaining traction, with over 80 Vault CRM deployments and a goal of exceeding 200 by fiscal 2026.
Salesforce is advancing AI at scale through Agentforce, a platform of prebuilt AI assistants embedded across its suite. Within 90 days of launch, Agentforce reached 3,000 paying customers and crossed $100 million in ARR. It connects with Tableau, MuleSoft, and Data Cloud to unify workflows and supports the Life Sciences Cloud Partner Network, which includes integrations with H1, ComplianceQuest, Box, and others. The company has also brought on AI-focused board members and continues to emphasize responsible adoption, aiming to augment human roles rather than replace them.
The Road Ahead: Who’s Better Positioned for CRM Leadership in Life Sciences?
Veeva is focused on finalizing its shift to the Vault platform, aiming to boost margins and accelerate innovation with full control over its tech stack. Its AI roadmap, including tools like Vault CRM Bot and Voice Control, is designed to enhance productivity and compliance for life sciences users. With strong early adoption of Vault CRM and expanding enterprise relationships, Veeva is positioning itself as the go-to vertical platform for the sector.
Salesforce is pursuing growth through its broad platform and expanding presence in life sciences via its dedicated cloud and AI-led offerings. Backed by a strong ecosystem and new integrations with healthcare partners, Salesforce is embedding Agentforce AI across its products. Its scale, flexibility, and ability to serve complex enterprise needs provide a strong foundation as it targets more specialized verticals like life sciences.
How Do Zacks Estimates Compare for VEEV & CRM?
The Zacks Consensus Estimate for VEEV’s fiscal 2026 sales implies a year-over-year growth of 12.78%. For fiscal 2026, the earnings per share are projected to be $7.64, up 15.76% year over year. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for CRM’s fiscal 2026 sales and earnings implies year-over-year growth of 8.64% and 10.78%, respectively. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
VEEV or CRM: Which Is the Smarter Buy?
Veeva and Salesforce represent two powerful but contrasting approaches to the life sciences CRM market—one focused on deep vertical integration, the other leveraging broad enterprise reach. Veeva currently holds a Zacks Rank #2 (Buy), reflecting positive sentiment and growing confidence in its post-Salesforce roadmap. Its Growth Score of ‘A’ highlights strong potential in revenue acceleration, margin expansion, and product adoption. Salesforce, meanwhile, carries a Zacks Rank #3 (Hold) but also maintains a Growth Score of ‘A’, supported by its scale, product breadth, and AI-led innovation strategy. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Both companies are positioned for long-term relevance, but Veeva’s focused strategy, platform control, and growing traction in life sciences give it the edge for investors seeking targeted exposure in this vertical. Salesforce remains a strong contender with scale and innovation, yet Veeva’s clarity and execution make it the more compelling pick in this CRM faceoff.